Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature
Abstract
Introduction
Mesothelioma is a rare and rapidly advancing tumor that usually emerges on the mesothelial surfaces of the pleura or peritoneum. Despite being a well-recognized rare disease for decades, the only approved primary treatment protocol has been platinum-based treatments plus pemetrexed, whether or not bevacizumab is administered. Immunotherapy-based immune checkpoint inhibitors demonstrated a promising antitumor efficacy in a variety of cancer types. This is a systematic review of the current role of durvalumab in the management of this condition.
Methods
A systematic search was carried out through the databases and search engines. Regardless of study design, line of therapy, mode of therapy, or Eastern Cooperative Oncology Group (ECOG) performance status, studies that primarily focused on the outcomes of treating this disease with durvalumab were eligible for inclusion. After the initial and full-text screenings, five studies were reviewed.
Results
The median age of the total 235 patients was 66.9 years. Males comprised 174 (74.04%) of the cases, with 61 (25.95%) cases being female. The Epithelioid mesothelioma subtype accounted for 194 (82.55%) of the patients. Durvalumab, in combination with pemetrexed cisplatin/carboplatin as therapy, was used in 109 (48.38%) cases. Durvalumab and tremelimumab were used in the treatment of 40 (17.02%) cases, of which 17 (7.23%) had retreatment with both immunotherapies. Among the patients who underwent durvalumab treatment, 69 (29.36% ) of the individuals previously received carboplatin/pemetrexed and cisplatin/pemetrexed.
Conclusion
Durvalumab can be utilized as an effective alternative for malignant pleural mesothelioma treatment, providing positive results and acceptable safety profiles.
References
- Calabrò, L., et al., Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. The Lancet Respiratory Medicine, 2021. 9(9): p. 969-976. doi:10.1016/S2213-2600(21)00043-6
- Ahmadzada, T., et al., Retrospective evaluation of the use of Pembrolizumab in malignant mesothelioma in a real-world Australian population. JTO Clinical and Research Reports, 2020. 1(4): p. 100075. doi:10.1016/j.jtocrr.2020.100075
- Forde, P.M., et al., Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature medicine, 2021. 27(11): p. 1910-1920. doi:10.1038/s41591-021-01541-0
- Arru, C., et al., Durvalumab plus tremelimumab in solid tumors: A systematic review. Advances in Therapy, 2021. 38(7): p. 3674-3693. doi:10.1007/s12325-021-01796-6
- Canova, S., et al., Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. ESMO open, 2022. 7(6): p. 100644. doi:10.1016/j.esmoop.2022.100644
- Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2016;387(10026):1405-14. doi:10.1016/S0140-6736(15)01238-6
- Nowak, A.K., et al., Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 2020. 21(9): p. 1213-1223. doi:10.1016/S1470-2045(20)30462-9
- Ferris, R., et al., Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Annals of Oncology, 2020. 31(7): p. 942-950. doi:10.1016/j.annonc.2020.04.001
- Muhialdeen, A.S., et al., Kscien’s List; A New Strategy to Discourage Predatory Journals and Publishers (Second Version). Barw Medical Journal, 2023. doi:10.58742/bmj.v1i1.14
- Ali, R.M., et al., Pembrolizumab (Anti-PD-1) in the management of malignant pleural mesothelioma: A systematic review of the current literature. Barw Medical Journal, 2023. doi:10.58742/bmj.v1i2.34
- Baas, P., et al., First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet, 2021. 397(10272): p. 375-386. doi:10.1016/S0140-6736(20)32714-8
- Maio, M., et al., Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology, 2017. 18(9): p. 1261-1273. doi:10.1016/S1470-2045(17)30446-1
- Calabrò, L., et al., Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018; 6 (6): 451–60. doi:10.1016/S2213-2600(18)30151-6
- Rohatgi, A. and J.M. Kirkwood, Beyond PD-1: the next frontier for immunotherapy in melanoma. Frontiers in Oncology, 2021. 11: p. 640314. doi:10.3389/fonc.2021.640314
- Bagge, R.O., et al., The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021. 31(2): p. 181-185. doi:10.1097/CMR.0000000000000719
- Alley, E.W., et al., Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. The Lancet Oncology, 2017. 18(5): p. 623-630. doi:10.1016/S1470-2045(17)30169-9
- Popat, S., et al., A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology, 2020. 31(12): p. 1734-1745. doi:10.1016/j.annonc.2020.09.009
- Gemelli, M., et al., Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis. Cancers, 2022. 14(24): p. 6063. doi:10.3390/cancers14246063
- Antonia, S., et al., Safety and antitumour activity in a phase 1b study of combined checkpoint blockade with anti-PD-L1 (durvalumab) and anti-CTLA4 (tremelimumab) in non-small cell lung cancer. The Lancet. Oncology, 2016. 17(3): p. 299. doi:10.1016/S1470-2045(15)00544-6
- Calabrò, L., et al., Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. The Lancet Respiratory Medicine, 2018. 6(6): p. 451-460. doi:10.1016/S2213-2600(18)30151-6
- Larkin, J., et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England journal of medicine, 2015. 373(1): p. 23-34. doi:10.1056/NEJMoa1504030
- Rizvi, N.A., et al., Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA oncology, 2020. 6(5): p. 661-674. doi:10.1001/jamaoncol.2020.0237
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.